Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Does hepatic oxidative stress enhance activation of nuclear factor-E2-related factor in patients with nonalcoholic steatohepatitis?

Takahashi Y, Kobayashi Y, Kawata K, Kawamura K, Sumiyoshi S, Noritake H, Watanabe S, Chida T, Souda K, Sakaguchi T, Nakamura H, Suda T.

Antioxid Redox Signal. 2014 Jan 20;20(3):538-43. doi: 10.1089/ars.2013.5470. Epub 2013 Aug 17.

PMID:
23822105
2.

Enhanced hepatic Nrf2 activation after ursodeoxycholic acid treatment in patients with primary biliary cirrhosis.

Kawata K, Kobayashi Y, Souda K, Kawamura K, Sumiyoshi S, Takahashi Y, Noritake H, Watanabe S, Suehiro T, Nakamura H.

Antioxid Redox Signal. 2010 Aug 1;13(3):259-68. doi: 10.1089/ars.2009.2903.

PMID:
20055754
3.

Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model.

Shimozono R, Asaoka Y, Yoshizawa Y, Aoki T, Noda H, Yamada M, Kaino M, Mochizuki H.

Mol Pharmacol. 2013 Jul;84(1):62-70. doi: 10.1124/mol.112.084269. Epub 2013 Apr 16.

4.

Nrf2 deletion causes "benign" simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet.

Wang C, Cui Y, Li C, Zhang Y, Xu S, Li X, Li H, Zhang X.

Lipids Health Dis. 2013 Nov 4;12:165. doi: 10.1186/1476-511X-12-165.

5.

Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice.

Sugimoto H, Okada K, Shoda J, Warabi E, Ishige K, Ueda T, Taguchi K, Yanagawa T, Nakahara A, Hyodo I, Ishii T, Yamamoto M.

Am J Physiol Gastrointest Liver Physiol. 2010 Feb;298(2):G283-94. doi: 10.1152/ajpgi.00296.2009. Epub 2009 Nov 19.

6.

Synergistic effect of cyanidin and PPAR agonist against nonalcoholic steatohepatitis-mediated oxidative stress-induced cytotoxicity through MAPK and Nrf2 transduction pathways.

Shih PH, Hwang SL, Yeh CT, Yen GC.

J Agric Food Chem. 2012 Mar 21;60(11):2924-33. doi: 10.1021/jf300005v. Epub 2012 Mar 9.

PMID:
22364184
7.

Experimental nonalcoholic fatty liver disease in mice leads to cytochrome p450 2a5 upregulation through nuclear factor erythroid 2-like 2 translocation.

Cui Y, Wang Q, Li X, Zhang X.

Redox Biol. 2013 Aug 24;1:433-40. doi: 10.1016/j.redox.2013.08.003. eCollection 2013.

8.

Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis.

Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, Tsujita T, Dillon JF, Ashford ML, Hayes JD.

Free Radic Biol Med. 2010 Jan 15;48(2):357-71. doi: 10.1016/j.freeradbiomed.2009.11.007. Epub 2009 Nov 13.

PMID:
19914374
9.

Liver injury attenuation by curcumin in a rat NASH model: an Nrf2 activation-mediated effect?

Li B, Wang L, Lu Q, Da W.

Ir J Med Sci. 2016 Feb;185(1):93-100. doi: 10.1007/s11845-014-1226-9. Epub 2014 Nov 11.

PMID:
25385666
10.

Activation of the Nrf2-ARE pathway in hepatocytes protects against steatosis in nutritionally induced non-alcoholic steatohepatitis in mice.

Lee LY, Köhler UA, Zhang L, Roenneburg D, Werner S, Johnson JA, Foley DP.

Toxicol Sci. 2014 Dec;142(2):361-74. doi: 10.1093/toxsci/kfu184. Epub 2014 Oct 6.

11.

Acute exposure to 3-methylcholanthrene induces hepatic oxidative stress via activation of the Nrf2/ARE signaling pathway in mice.

Jin Y, Miao W, Lin X, Pan X, Ye Y, Xu M, Fu Z.

Environ Toxicol. 2014 Dec;29(12):1399-408. doi: 10.1002/tox.21870. Epub 2013 May 27.

PMID:
23712962
12.

Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease.

Nomoto K, Tsuneyama K, Takahashi H, Murai Y, Takano Y.

Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):71-5.

PMID:
18091316
13.

Levels of the oxidative stress marker γ-glutamyltranspeptidase at different stages of nonalcoholic fatty liver disease.

Irie M, Sohda T, Iwata K, Kunimoto H, Fukunaga A, Kuno S, Yotsumoto K, Sakurai K, Iwashita H, Hirano G, Ueda SI, Yokoyama K, Morihara D, Nishizawa S, Anan A, Takeyama Y, Sakamoto M, Shakado S, Sakisaka S.

J Int Med Res. 2012;40(3):924-33.

PMID:
22906265
14.

Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease.

Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ.

Drug Metab Dispos. 2010 Dec;38(12):2293-301. doi: 10.1124/dmd.110.035006. Epub 2010 Aug 30.

15.

The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism.

Chambel SS, Santos-Gonçalves A, Duarte TL.

Biomed Res Int. 2015;2015:597134. doi: 10.1155/2015/597134. Epub 2015 May 18. Review.

16.

Nrf2-inducing anti-oxidation stress response in the rat liver--new beneficial effect of lansoprazole.

Yamashita Y, Ueyama T, Nishi T, Yamamoto Y, Kawakoshi A, Sunami S, Iguchi M, Tamai H, Ueda K, Ito T, Tsuruo Y, Ichinose M.

PLoS One. 2014 May 20;9(5):e97419. doi: 10.1371/journal.pone.0097419. eCollection 2014.

17.
18.

Nuclear erythroid 2-related factor 2: a novel potential therapeutic target for liver fibrosis.

Yang JJ, Tao H, Huang C, Li J.

Food Chem Toxicol. 2013 Sep;59:421-7. doi: 10.1016/j.fct.2013.06.018. Epub 2013 Jun 20. Review.

PMID:
23793039
19.

Oxidative stress indicated by elevated expression of Nrf2 and 8-OHdG promotes hepatocellular carcinoma progression.

Ma-On C, Sanpavat A, Whongsiri P, Suwannasin S, Hirankarn N, Tangkijvanich P, Boonla C.

Med Oncol. 2017 Apr;34(4):57. doi: 10.1007/s12032-017-0914-5. Epub 2017 Mar 9.

PMID:
28281193
20.

Hepatocyte-specific sirtuin 6 deletion predisposes to nonalcoholic steatohepatitis by up-regulation of Bach1, an Nrf2 repressor.

Ka SO, Bang IH, Bae EJ, Park BH.

FASEB J. 2017 Sep;31(9):3999-4010. doi: 10.1096/fj.201700098RR. Epub 2017 May 23.

PMID:
28536120

Supplemental Content

Support Center